Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients

Creative Commons License

CENGİZ SEVAL G., ÖZCAN M.

JOURNAL OF CLINICAL MEDICINE, cilt.4, sa.3, ss.441-459, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 4 Sayı: 3
  • Basım Tarihi: 2015
  • Doi Numarası: 10.3390/jcm4030441
  • Dergi Adı: JOURNAL OF CLINICAL MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.441-459
  • Anahtar Kelimeler: acute myeloid leukemia, adolescent and young adults, treatment, BONE-MARROW-TRANSPLANTATION, STEM-CELL TRANSPLANTATION, ACUTE MYELOGENOUS LEUKEMIA, HIGH-DOSE CYTARABINE, INTERNATIONAL EXPERT PANEL, CHILDRENS ONCOLOGY GROUP, RANDOMIZED PHASE-III, RISK ACUTE-LEUKEMIA, GEMTUZUMAB OZOGAMICIN, HEMATOLOGIC MALIGNANCIES
  • Ankara Üniversitesi Adresli: Evet

Özet

The objectives of this review were to discuss standard and investigational treatment strategies for adolescent and young adult with acute myeloid leukemia, excluding acute promyelocytic leukemia. Acute myeloid leukemia (AML) in adolescent and young adult patients (AYAs) may need a different type of therapy than those currently used in children and older patients. As soon as AML is diagnosed, AYA patient should be offered to participate in well-designed clinical trials. The standard treatment approach for AYAs with AML is remission induction chemotherapy with an anthracycline/cytarabine combination, followed by either consolidation chemotherapy or stem cell transplantation, depending on the ability of the patient to tolerate intensive treatment and cytogenetic features. Presently, continuing progress of novel drugs targeting specific pathways in acute leukemia may bring AML treatment into a new era.